Sign In
Buy CSTL
$24.69
-0.795 (-3.12%)
At Close: Jul 24, 2026
Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
05:26pm, Monday, 01'st Mar 2021
Castle Biosciences, Inc. (CSTL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #SkinCancer--Castle will release its financial results for the fourth quarter and year-ended December 31, 2020, after the close of market on Monday, March
Castle Biosciences to Present at Upcoming Investor Conferences
07:00am, Monday, 08'th Feb 2021
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences is scheduled to present a company overview at upcoming investor conferences.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle today announced virtual posters on its three skin cancer gene expression profile tests at the 19th Annual South Beach Symposium
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatolo
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2020 Results
07:00am, Wednesday, 13'th Jan 2021
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Castle--Castle today announced certain unaudited preliminary performance results for the fourth quarter and full-year 2020.
Castle Biosciences to Present at the 23rd Annual Needham Virtual Growth Conference
07:00am, Monday, 04'th Jan 2021
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle is scheduled to present a company overview at the 23rd Annual Needham Virtual Growth Conference on Jan. 15, 2021.
Castle Biosciences Announces Early Repayment of Debt
07:00am, Tuesday, 22'nd Dec 2020
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #skincancer--Castle today announced it prepaid in full its outstanding term loan facility.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle Biosciences today announced the closing of its previously announced underwritten public offering.
Castle Biosciences Announces Pricing of $232 Million Public Offering of Common Stock
08:01pm, Tuesday, 15'th Dec 2020
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle Biosciences announced today the pricing of its underwritten public offering.
Castle Biosciences Announces Commencement of Proposed Public Offering of Common Stock
04:45pm, Monday, 14'th Dec 2020
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle announced today that it has commenced a proposed underwritten public offering.
Castle Biosciences Announces Publication of Peer-Reviewed Publication Demonstrating the Clinical Impact of DecisionDx®-Melanoma
07:00am, Friday, 04'th Dec 2020
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle Biosciences Announces Publication of Peer-Reviewed Publication Demonstrating the Clinical Impact of DecisionDx®-Melanoma
Castle Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
05:00pm, Monday, 23'rd Nov 2020
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #cancerdiagnostics--Castle Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle Biosciences Announces Publication of Clinical Validation and Utility Data for DecisionDx® DiffDx™-Melanoma for Suspicious Pi
Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q3 2020 Results - Earnings Call Transcript
11:57pm, Monday, 09'th Nov 2020
Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q3 2020 Results - Earnings Call Transcript
